ERJ Open Research最新文献

{"title":"Does adding digital inhalers to asthma triple therapy result in quadruple therapy?","authors":"Job F M van Boven, Amber A Eikholt","doi":"10.1183/23120541.01026-2024","DOIUrl":"10.1183/23120541.01026-2024","url":null,"abstract":"<p><p><b>Digital inhalers: adequate subgroup targeting and cost-effective implementation in asthma care remain key challenges</b> https://bit.ly/3UTWtWv.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The lung proteome in HIV-associated obstructive lung disease.","authors":"Sarah Samorodnitsky, Danielle Weise, Eric F Lock, Ken M Kunisaki, Alison Morris, Janice M Leung, Monica Kruk, Laurie Parker, Pratik Jagtap, Timothy J Griffin, Chris H Wendt","doi":"10.1183/23120541.00204-2024","DOIUrl":"10.1183/23120541.00204-2024","url":null,"abstract":"<p><strong>Rationale: </strong>Obstructive lung disease is increasingly common among persons living with HIV (PLWH). There are currently no validated biomarkers that identify individuals at risk of developing obstructive lung disease (OLD), and specific mechanisms contributing to HIV-associated OLD remain elusive, independent of smoking. We sought to identify biomarkers and biological pathways associated with OLD using a broad proteomic approach.</p><p><strong>Methods: </strong>We performed tandem mass tagging and mass spectrometry (MS) analysis on bronchoalveolar lavage fluid samples from persons living with HIV with OLD (n=26) and without OLD (n=26). We combined untargeted MS with a targeted SomaScan aptamer-based approach. We used Pearson correlation tests to identify associations between each protein and lung function (forced expiratory volume in 1 s (FEV₁) % pred). We adjusted for multiple comparisons using a false discovery rate adjustment. Significant proteins were entered into a pathway over-representation analysis. Protein-driven endotypes were constructed using K-means clustering.</p><p><strong>Measurements and main results: </strong>We identified over 3800 proteins by MS and identified 254 proteins that correlated with FEV₁ % pred when we combined the MS and SomaScan proteomes when adjusting for smoking status. Pathway analysis revealed cell adhesion molecules as significant.</p><p><strong>Conclusions: </strong>Protein expression differs in the lung of PLWH and decreased lung function (FEV₁ % pred). Pathway analysis reveals cell adhesion molecules having potentially important roles in this process.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating digital adherence support in asthma: the ADITION non-interventional study.","authors":"Holger Woehrle, Jens Driemert, Lukas Jerrentrup, Conrad Schiefer, Gregor Bushart, Inessa Schwab Sauerbeck","doi":"10.1183/23120541.00734-2024","DOIUrl":"10.1183/23120541.00734-2024","url":null,"abstract":"<p><strong>Background: </strong>Poor adherence to asthma maintenance therapy is associated with worse outcomes. A solution could be digital adherence support. This study evaluated asthma control and adherence in patients using mometasone furoate/indacaterol/glycopyrronium (MF/IND/GLY) with a digital support system or using any inhaled corticosteroid/long-acting β₂-agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) combination without support.</p><p><strong>Methods: </strong>This prospective, non-interventional, multicentre, open-label study enrolled adults with asthma in Germany. Prior to inclusion, treatment was initiated with MF/IND/GLY with digital support or with any ICS/LABA/LAMA without digital support. The primary end-point was change in Asthma Control Test (ACT) at 6 months.</p><p><strong>Results: </strong>Of 222 and 203 patients in the MF/IND/GLY plus digital support and ICS/LABA/LAMA groups, 76.1% and 74.9% completed follow-up, respectively. Baseline mean ACT total scores were 17.0 and 14.7, with mean changes from baseline at 6 months of 3.0 and 4.1, respectively; following propensity matching (n=92 per group), mean changes were similar in the two groups, with overlapping 95% confidence intervals (2.9 (95% CI 1.9-3.9) and 4.0 (95% CI 3.0-5.1), respectively). At enrolment, patients were overall moderately adherent to maintenance therapy, with limited changes over the study. The overall incidence of adverse events was similar in the two groups (29.5% and 27.3% of patients, respectively).</p><p><strong>Conclusions: </strong>Patients using MF/IND/GLY with digital support had similar improvements in asthma control to those receiving ICS/LABA/LAMA alone, with minimal changes in adherence. These results illustrate the challenges in evaluating asthma control and adherence in non-interventional studies. Further studies are required to evaluate the value of digital support systems and how they can be used to optimise inhaler adherence.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The interstitial lung disease patient pathway: from referral to diagnosis.","authors":"Graham Lough, Rayid Abdulqawi, Gina Amanda, Katerina Antoniou, Arata Azuma, Milind Baldi, Ahmed Bayoumy, Jürgen Behr, Elisabeth Bendstrup, Demosthenes Bouros, Kevin Brown, Nazia Chaudhuri, Tamera J Corte, Vincent Cottin, Bruno Crestani, Kevin R Flaherty, Ian Glaspole, Leticia Kawano-Dourado, Michael P Keane, Martin Kolb, Fernando J Martinez, Maria Molina-Molina, Iñigo Ojanguren, Laurence Pearmain, Ganesh Raghu, Paola Rottoli, Stefan C Stanel, Gabriela Tabaj, Carlo Vancheri, Brenda Varela, Bonnie Wang, Athol Wells, Pilar Rivera-Ortega","doi":"10.1183/23120541.00899-2024","DOIUrl":"10.1183/23120541.00899-2024","url":null,"abstract":"<p><strong>Background: </strong>Suspected interstitial lung disease (ILD) patients may be referred to an ILD-specialist centre or a non-ILD-specialist centre for diagnosis and treatment. Early referral and management of patients at ILD-specialist centres has been shown to improve survival and reduce hospitalisations. The COVID-19 pandemic has affected the ILD patient diagnostic pathway and prompted centres to adapt. This study investigates and contrasts ILD patient pathways in ILD-specialist and non-ILD-specialist centres, focusing on referrals, caseloads, diagnostic tools, multi-disciplinary team (MDT) meeting practices and resource accessibility.</p><p><strong>Methods: </strong>Conducted as a cross-sectional study, a global self-selecting survey ran from September 2022 to January 2023. Participants included ILD specialists and healthcare professionals (HCPs) from ILD-specialist centres and non-ILD-specialist centres.</p><p><strong>Results: </strong>Of 363 unique respondents from 64 countries, 259 were from ILD-specialist centres and 104 from non-ILD-specialist centres. ILD centres had better resource availability, exhibiting higher utilisation of diagnostic tests (median: 12 tests) than non-ILD centres (nine tests) and better access to specialist professions attending MDT meetings (median: six professions at meeting) in specialist centres than non-ILD centres (three professions at meeting). Transitioning to virtual MDT meetings allowed HCPs from other locations to join meetings in nearly 90% of all centres, increasing regular participation in 60% of specialist centres and 72% of non-ILD centres. For treatment of patients, specialist centres had better access to antifibrotic drugs (91%) compared to non-ILD centres (60%).</p><p><strong>Conclusions: </strong>Diagnostic pathways for ILD patients diverged between specialist centres and non-ILD centres. Disparities in resource and specialist availability existed between centres.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in ventilatory muscle recruitment and work of breathing in COPD and interstitial lung disease.","authors":"Ben Fabry","doi":"10.1183/23120541.00881-2024","DOIUrl":"10.1183/23120541.00881-2024","url":null,"abstract":"<p><p><b>Providing more detailed explanations would help readers better understand and correctly interpret the reported data</b> https://bit.ly/3N72niA.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of CFTR modulators in patients with interstitial lung disease caused by ABCA3 transporter deficiency.","authors":"Mathilde Le Brun, Nadia Nathan, Camille Louvrier, Marie Legendre, Severine Feuillet, Justine Frija-Masson, Mwetty Onanga, Lise Morer, Marie-Pierre Debray, Isabelle Fajac, Pierre-Régis Burgel, Sylvain Marchand-Adam, Bruno Crestani, Raphaël Borie","doi":"10.1183/23120541.00701-2024","DOIUrl":"10.1183/23120541.00701-2024","url":null,"abstract":"<p><p><b>CFTR modulators may be valuable therapy for patients with ABCA3 pathogenic variants</b> https://bit.ly/3TMWKK9.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874218/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung recruitment manoeuvre strategies in paediatric intensive care units across Europe.","authors":"Elisa Poletto, Marco Daverio, Robert George Theodoor Blokpoel, Gloria Brigiari, Dario Gregori, Marti Pons-Odena, Alvise Tosoni","doi":"10.1183/23120541.00781-2024","DOIUrl":"10.1183/23120541.00781-2024","url":null,"abstract":"<p><strong>Introduction: </strong>In severe paediatric acute respiratory distress syndrome (PARDS) lung recruitment manoeuvres (LRMs) may be applied to improve oxygenation, but their application is still controversial. The aim of this survey is to report what the current practice is across European paediatric intensive care units (PICUs).</p><p><strong>Methods: </strong>An online survey was distributed to PICUs in 19 European countries targeting paediatric intensivists, nurses and respiratory therapists. One reply per unit was allowed.</p><p><strong>Results: </strong>151 PICUs out of 276 (54.8%) responded. Of those, 75.9% have more than 300 admissions per year and 45.1% are extracorporeal membrane oxygenation (ECMO) centres. LRMs are employed in 78.9% of surveyed PICUs. Twenty-three out of 105 (21.9%) PICUs have a standardised protocol. LRMs are mainly performed by physicians (99%), supported by nurses (38.4%) and/or respiratory therapists (11.5%). The main reported contraindications are air leak (86.7%), haemodynamic instability (75.2%) and intracranial hypertension (63.8%). Staircase recruitment manoeuvres (SRMs) are the most commonly (69.5%) practiced LRMs, while sustained inflation is used in 44.8% of PICUs, alone or in addition to SRMs. The success of LRMs is measured through oxygenation improvement (oxygenation index or arterial oxygen tension/inspiratory oxygen fraction). Profound hypotension is the most reported complication (49.5%), while 35.2% did not report any complication. Lack of familiarity is the main obstacle to the application of LRMs (67.9%).</p><p><strong>Conclusions: </strong>To our best knowledge this is the first survey providing an overview of current LRMs application among European PICUs. Practise is diverse among countries and PICUs. Further research is necessary to build stronger evidence to support a more standard application of LRMs.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unravelling the role of heart rate recovery in bronchiectasis: do we need to establish a cutoff value?","authors":"Arietta Spinou, Ioannis D Laoutaris","doi":"10.1183/23120541.01119-2024","DOIUrl":"10.1183/23120541.01119-2024","url":null,"abstract":"<p><p><b>Heart rate recovery after a field walking test could be a key indicator in bronchiectasis management. Establishing a clear cutoff value in future research will enhance its clinical utility. #HeartRateRecovery #Bronchiectasis #PulmonaryRehabilitation</b> https://bit.ly/4fNAWXe.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted proteomics in extracellular vesicles identifies biomarkers predictive for therapeutic response in sarcoidosis.","authors":"Raisa Kraaijvanger, Montse Janssen Bonás, Ioanna Paspali, Jan C Grutters, Marcel Veltkamp, Dominique P V de Kleijn, Coline H M van Moorsel","doi":"10.1183/23120541.00672-2024","DOIUrl":"10.1183/23120541.00672-2024","url":null,"abstract":"<p><strong>Background: </strong>∼30% of patients with sarcoidosis, a systemic granulomatous disease of unknown cause, need treatment to alleviate symptoms or prevent organ damage. Prednisone and methotrexate (MTX) are the most commonly used drugs; however, success of treatment varies from patient to patient. In this study, we search for biomarkers and pathways that predict response to treatment with prednisone or MTX in extracellular vesicles (EVs).</p><p><strong>Methods: </strong>A targeted proteomics approach (OLINK Bioscience) was used in which 92 proteins were measured in two baseline EV fractions in 32 patients treated for pulmonary sarcoidosis (eight responders and eight non-responders each for prednisone and MTX). The top three proteins were replicated in 62 prednisone- and 76 MTX-treated patients.</p><p><strong>Results: </strong>We identified 11 differentially expressed proteins (DEPs) between responders and non-responders to prednisone treatment, and 16 DEPs for patients treated with MTX. Reactome pathway analysis showed DEPs in prednisone to be involved in nuclear factor kappa B and interleukin signalling pathways. The DEPs in MTX were involved in transduction of GPI-anchored proteins and MAPK signalling pathway. CHI3L1 for prednisone and CPA1 for MTX were replicated as significant predictors of response.</p><p><strong>Conclusion: </strong>This study is the first to show that in pulmonary sarcoidosis the response to treatment with prednisone or MTX can be predicted at baseline by different EV proteins active in different pathways. Using these markers and associated pathways to identify patients with a high probability of response to therapy will aid personalised treatment choice and improve treatment outcome.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences of ventilatory muscle recruitment and work of breathing in COPD and interstitial lung disease: clarifications.","authors":"Jeferson George Ferreira, André L P de Albuquerque","doi":"10.1183/23120541.00946-2024","DOIUrl":"10.1183/23120541.00946-2024","url":null,"abstract":"<p><p><b>These clarifications are important for understanding the respiratory mechanics in COPD and ILD. This response provides the necessary clarification and reinforces the validity of the study's conclusions.</b> https://bit.ly/48k1Cws.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}